We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$4.27B 29.08%
50,057,277
– –
INCY icon
2
Incyte
INCY
$25.5B
$2.37B 16.15%
31,976,557
+364
+0% +$29.4K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.43B
$1.47B 10%
40,854,586
+1,562,500
+4% +$47.4M
ONC
4
BeOne Medicines Ltd
ONC
$33.8B
$1.44B 9.81%
11,777,285
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$809M 5.5%
8,258,068
– –
AMRN
6
Amarin Corp
AMRN
$299M
$630M 4.28%
2,077,214
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$627M 4.27%
9,244,665
-16,257
-0.2% -$1.12M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$512M 3.48%
7,589,294
– –
ASND icon
9
Ascendis Pharma A/S
ASND
$16.7B
$327M 2.22%
3,390,270
– –
NVTA
10
DELISTED
Invitae Corporation
NVTA
$169M 1.15%
8,792,678
+4,890,257
+125% +$115M
KOD icon
11
Kodiak Sciences
KOD
$2.4B
$132M 0.89%
9,145,116
+1
+0% +$13
NBIX icon
12
Neurocrine Biosciences
NBIX
$18.2B
$128M 0.87%
1,415,283
– –
ARGX icon
13
argenx
ARGX
$55.1B
$116M 0.79%
1,019,557
– –
HRTX icon
14
Heron Therapeutics
HRTX
$91.6M
$111M 0.76%
6,018,104
– –
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$102M 0.69%
1,307,220
-1,206,242
-48% -$113M
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.5B
$101M 0.69%
1,169,278
– –
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$79.1M 0.54%
1,517,237
+500,931
+49% +$26.6M
ONCE
18
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$72.9M 0.5%
751,927
– –
TCDA
19
DELISTED
Tricida, Inc. Common Stock
TCDA
$60.8M 0.41%
1,969,905
– –
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7.3B
$58.5M 0.4%
2,708,200
– –
IGMS
21
DELISTED
IGM Biosciences
IGMS
$55.8M 0.38%
+3,144,000
New +$63.5M
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$55.5M 0.38%
2,345,496
+543,801
+30% +$16.1M
CERS icon
23
Cerus
CERS
$577M
$55.4M 0.38%
10,749,937
– –
DBVT
24
DBV Technologies
DBVT
$800M
$47.4M 0.32%
550,956
– –
PRNB
25
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$46.7M 0.32%
1,654,029
-133,778
-7% -$4.91M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Baker Bros. Advisors held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Baker Bros. Advisors's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Baker Bros. Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 2 in Q3 2019.
  • Baker Bros. Advisors's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.